-
公开(公告)号：US11136400B2
公开(公告)日：2021-10-05
申请号：US17145001
申请日：2021-01-08
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Eiji Inoue , Akio Yamada , Tomomi Kawakatsu , Toshio Imai , Maki Deguchi , Aki Nakatani
Abstract: Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient.
A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.-
公开(公告)号：US10947313B2
公开(公告)日：2021-03-16
申请号：US16915412
申请日：2020-06-29
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Eiji Inoue , Akio Yamada , Tomomi Kawakatsu , Toshio Imai , Maki Deguchi , Aki Nakatani
IPC: C07K16/28 , A61K39/395 , A61P25/28 , A61K39/00
Abstract: Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient.
A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.-
公开(公告)号：US20190077860A1
公开(公告)日：2019-03-14
申请号：US15753611
申请日：2016-09-06
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Ryota Taguchi , Toshio Imai , Eiji Inoue , Akio Yamada , Aki Nakatani , Toshifumi Hirayama , Yuichi Ono , Shunsuke Ito
CPC classification number: C07K16/28 , A61K2039/505 , A61P21/02 , A61P25/28 , C07K16/2866 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N15/62
Abstract: It is intended to provide an anti-EphA4 antibody or an EphA4-binding fragment thereof which is capable of binding to EphA4 and inhibiting the binding between EphA4 and its ligand, and a pharmaceutical composition comprising the anti-EphA4 antibody or the EphA4-binding fragment thereof as an active ingredient. A mouse anti-EphA4 antibody having binding affinity for EphA4 was obtained, and the sequences of complementarity-determining regions (CDRs) of the mouse anti-EphA4 antibody were identified. This allowed for preparation of a humanized antibody comprising the CDR sequences of the mouse anti-EphA4 antibody in heavy chain variable region and light chain variable region.
-
公开(公告)号：US20150056201A1
公开(公告)日：2015-02-26
申请号：US14528434
申请日：2014-10-30
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Keiko Yamaguchi , Toshio Imai , Kenzo Muramoto
IPC: C07K16/18
CPC classification number: C07K16/18 , C07K16/2803 , C07K2317/24 , C07K2317/569 , C07K2317/76 , G01N33/56972 , G01N2333/075 , G01N2333/085
Abstract: The inventors discovered that the adhesion molecule CAR, known to be localized in intracellular adhesion sites, functioned as an adhesion molecule for activated lymphocytes. Further, the inventors identified CARL, a novel CAR ligand expressed in lymphocytes, and clarified that the ligand was expressed selectively in Th1 cells. In addition, they found that anti-CAR antibodies could inhibit the adhesion of activated lymphocytes to CAR molecules. Thus, the present invention provides methods for detecting Th1 cells using CAR or anti-CARL antibodies, and methods of screening for inhibitors suppressing the adhesion of Th1 cells using the binding between CAR and CARL as an index. Furthermore, the present invention relates to methods of screening for inhibitors of the binding between CAR and CARL, antibodies that inhibit the binding between CAR and CARL, and therapeutic compositions comprising these antibodies. These are expected to be useful in diagnosing diseases, such as inflammation, in which infiltration of Th1 cells is involved, and in providing pharmaceutical agents for alleviating such diseases.
Abstract translation: 本发明人发现已知局限在细胞内粘附位点的粘附分子CAR用作活化淋巴细胞的粘附分子。 此外，本发明人鉴定了CARL，一种在淋巴细胞中表达的新型CAR配体，并阐明了配体在Th1细胞中有选择性表达。 此外，他们发现抗CAR抗体可以抑制活化淋巴细胞对CAR分子的粘附。 因此，本发明提供了使用CAR或抗CARL抗体检测Th1细胞的方法，以及使用CAR和CARL之间的结合作为指标筛选抑制Th1细胞粘附的抑制剂的方法。 此外，本发明涉及筛选CAR和CARL之间的结合抑制剂的方法，抑制CAR和CARL之间的结合的抗体以及包含这些抗体的治疗组合物。 预期这些可用于诊断涉及Th1细胞浸润的疾病，例如炎症，以及提供减轻这些疾病的药物。
-
公开(公告)号：US09453070B2
公开(公告)日：2016-09-27
申请号：US14528434
申请日：2014-10-30
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Keiko Yamaguchi , Toshio Imai , Kenzo Muramoto
IPC: A61K39/395 , C07K16/18 , C07K16/28 , G01N33/569
CPC classification number: C07K16/18 , C07K16/2803 , C07K2317/24 , C07K2317/569 , C07K2317/76 , G01N33/56972 , G01N2333/075 , G01N2333/085
Abstract: The inventors discovered that the adhesion molecule CAR, known to be localized in intracellular adhesion sites, functioned as an adhesion molecule for activated lymphocytes. Further, the inventors identified CARL, a novel CAR ligand expressed in lymphocytes, and clarified that the ligand was expressed selectively in Th1 cells. In addition, they found that anti-CAR antibodies could inhibit the adhesion of activated lymphocytes to CAR molecules. Thus, the present invention provides methods for detecting Th1 cells using CAR or anti-CARL antibodies, and methods of screening for inhibitors suppressing the adhesion of Th1 cells using the binding between CAR and CARL as an index. Furthermore, the present invention relates to methods of screening for inhibitors of the binding between CAR and CARL, antibodies that inhibit the binding between CAR and CARL, and therapeutic compositions comprising these antibodies. These are expected to be useful in diagnosing diseases, such as inflammation, in which infiltration of Th1 cells is involved, and in providing pharmaceutical agents for alleviating such diseases.
-
Patent Agency Ranking
公开(公告)号：US20160046707A1
公开(公告)日：2016-02-18
申请号：US14816989
申请日：2015-08-03
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Toshio Imai , James Bradford Kline , Tetsu Kawano , Luigi Grasso , Yoshimasa Sakamoto , Jared Spidel , Miyuki Nishimura , Kenzo Muramoto , Tatsuo Horizoe
CPC classification number: C07K16/24 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2317/92 , G01N33/6863 , G01N2333/521
Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.
Abstract translation: 本发明涉及对人CC趋化因子配体20（CCL20）具有结合特异性的新型人源化，嵌合和鼠抗体。 本发明还涉及所述抗体的重链和轻链。 本发明还涉及分离的核酸，重组载体和宿主细胞，其包含编码所述抗体的重链和/或轻链的序列，以及制备所述抗体的方法。 本发明的抗CCL20抗体可用于治疗例如炎性和自身免疫性疾病和癌症的治疗应用。
-
公开(公告)号：US09200066B2
公开(公告)日：2015-12-01
申请号：US13840851
申请日：2013-03-15
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Keiko Yamaguchi , Toshio Imai , Kenzo Muramoto
IPC: C07K16/00 , C07K16/28 , C07K16/18 , G01N33/569
CPC classification number: C07K16/18 , C07K16/2803 , C07K2317/24 , C07K2317/569 , C07K2317/76 , G01N33/56972 , G01N2333/075 , G01N2333/085
Abstract: The inventors discovered that the adhesion molecule CAR, known to be localized in intracellular adhesion sites, functioned as an adhesion molecule for activated lymphocytes. Further, the inventors identified CARL, a novel CAR ligand expressed in lymphocytes, and clarified that the ligand was expressed selectively in Th1 cells. In addition, they found that anti-CAR antibodies could inhibit the adhesion of activated lymphocytes to CAR molecules. Thus, the present invention provides methods for detecting Th1 cells using CAR or anti-CARL antibodies, and methods of screening for inhibitors suppressing the adhesion of Th1 cells using the binding between CAR and CARL as an index. Furthermore, the present invention relates to methods of screening for inhibitors of the binding between CAR and CARL, antibodies that inhibit the binding between CAR and CARL, and therapeutic compositions comprising these antibodies. These are expected to be useful in diagnosing diseases, such as inflammation, in which infiltration of Th1 cells is involved, and in providing pharmaceutical agents for alleviating such diseases.
-
公开(公告)号：US11034769B1
公开(公告)日：2021-06-15
申请号：US17145001
申请日：2021-01-08
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Eiji Inoue , Akio Yamada , Tomomi Kawakatsu , Toshio Imai , Maki Deguchi , Aki Nakatani
Abstract: Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient.
A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.-
公开(公告)号：US10428140B2
公开(公告)日：2019-10-01
申请号：US15753611
申请日：2016-09-06
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Ryota Taguchi , Toshio Imai , Eiji Inoue , Akio Yamada , Aki Nakatani , Toshifumi Hirayama , Yuichi Ono , Shunsuke Ito
Abstract: It is intended to provide an anti-EphA4 antibody or an EphA4-binding fragment thereof which is capable of binding to EphA4 and inhibiting the binding between EphA4 and its ligand, and a pharmaceutical composition comprising the anti-EphA4 antibody or the EphA4-binding fragment thereof as an active ingredient. A mouse anti-EphA4 antibody having binding affinity for EphA4 was obtained, and the sequences of complementarity-determining regions (CDRs) of the mouse anti-EphA4 antibody were identified. This allowed for preparation of a humanized antibody comprising the CDR sequences of the mouse anti-EphA4 antibody in heavy chain variable region and light chain variable region.
-
公开(公告)号：US20190002588A1
公开(公告)日：2019-01-03
申请号：US16063515
申请日：2017-01-11
Inventor： Toshinori Nakayama , Motoko Kimura , Koji Hayashizaki , Toshifumi Hirayama , Jungo Kakuta , Yoshimasa Sakamoto , Ryu Gejima , Daisuke Tokita , Kenzo Muramoto , Toshio Imai
Abstract: The present invention provides an anti-Myl9 antibody or a Myl9 binding fragment thereof that binds to Myl9 and may inhibit the interaction between Myl9 and CD69 in humans, as well as a pharmaceutical composition comprising the same. A mouse anti-human/mouse Myl9 monoclonal antibody having binding affinity against Myl9 was obtained, and the sequence for the complementarity determining region (CDR) of said mouse anti-human/mouse Myl9 monoclonal antibody was identified. Accordingly, a humanized antibody comprising the CDR sequence of said mouse anti-human/mouse Myl9 monoclonal antibody in the variable region of heavy and light chains was produced.
-
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.022 seconds)
